Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-5209

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-5209). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5209 3)

Label for Losartan Potassium 50 mg tablets by NuCare Pharmaceuticals, Inc. The label states the product contains 30 film-coated tablets, each with 50 mg Losartan Potassium USP. Tablets are oval shaped, white/off-white, scored, with debossed markings '1' and '6'. Includes NDC 68071-5209-3 and storage instructions to keep at 68-77°F. Warning to keep out of reach of children and Rx only designation are present.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over a 60-month study period for Atenolol and Losartan Potassium. The graph shows a slightly lower rate for Losartan Potassium with an adjusted risk reduction of 13%, statistically significant with p=0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over study months between Atenolol and Losartan potassium. The graph shows study months on the x-axis and percentage of patients on the y-axis, with a reported adjusted risk reduction of 25% and p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A clinical study forest plot depicting Primary Endpoint Events within demographic subgroups comparing Losartan Potassium and Atenolol. It shows event rates (%) and hazard ratios (95% CI) for Primary Composite and Stroke (Fatal/Non-Fatal) outcomes across various groups by age, gender, race, ISH status, diabetes, and history of cardiovascular disease. The plot includes symbols proportional to sample size and a horizontal axis illustrating favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and Placebo groups. The graph shows risk reduction of 16.1% with a p-value of 0.022, indicating the statistical significance of the difference.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium, showing its characteristic biphenyl-tetrazole moiety, chlorinated imidazole ring, and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.